VP-102: Clinical Trials

3 trials of VP-102, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 not yet recruiting. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Not yet recruiting 1

Follow VP-102: new trials by email Literature Review of VP-102 trials Research Report on VP-102

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
VP-102 - Common Warts, Common Warts (Verruca Vulgaris)
Phase 2Not yet recruitingVerrica Pharmaceuticals Inc.302026-10-012026-10-20
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
VP-102 and applicator, Placebo - Condylomata Acuminata, Papillomavirus Infections
Phase 2CompletedVerrica Pharmaceuticals Inc.1052019-06-252024-11-27
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
VP-102 with applicator - Molluscum Contagiosum
Phase 2CompletedVerrica Pharmaceuticals Inc.332017-06-082021-08-11

Conditions studied

Warts (2)  ·  Condylomata Acuminata (1)  ·  Molluscum Contagiosum (1)  ·  Papillomavirus Infections (1)  ·  Sexually Transmitted Diseases (1)  ·  Sexually Transmitted Diseases, Viral (1)  ·  Skin Diseases (1)  ·  Skin Diseases, Infectious (1)  ·  Skin Diseases, Viral (1)  ·  Virus Diseases (1)

Sponsors

Verrica Pharmaceuticals Inc. (3)

Countries

United States (3)

Top investigators

Gary Goldenberg, MD (1)  ·  Scott Guenthner, MD (1)

Results publications

PMID 33400412, PMID 34515985